UBS lowered the firm’s price target on Iqvia (IQV) to $185 from $255 and keeps a Buy rating on the shares. The Technology & Analytics Solutions recovery is on track, but the firm sees incremental weakness in Research & Development Solutions, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $161 from $195 at Baird
- IQVIA Holdings: Strong Financial Performance and Promising Outlook Amidst Market Challenges
- Iqvia price target lowered to $165 from $170 at Barclays
- IQVIA Holdings Reports Strong Q1 2025 Results
- Resilience and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Industry Challenges